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the blood and tissues.2,3 The cells are character‑
ized by a highly active metabolism; they produce 
elements of the basement membrane, intercellular 
junctions, and numerous substances that regulate 
blood vessel tone and blood flow.1,3 In addition, 
the endothelium plays a key role in the normal 
functioning of the coagulation system and fibrino‑
lysis through protein synthesis and interactions 
with blood platelets, and regulates the inflamma‑
tory response by acting on inflammatory cells.1,2,4 
Activation of the endothelium triggers an increase 
in leukocyte adhesion, endothelial cell permeabili‑
ty to inflammatory cells, tone of the smooth mus‑
cular coat, and activity of the coagulation system. 
IntroductIon Inflammatory bowel diseases 
(IBDs), including Crohn disease (CD) and ulcer‑
ative colitis (UC), constitute chronic conditions, 
the etiology of which is not fully understood.
Patients with IBD are genetically predisposed 
to pathological interactions among intestinal mi‑
croflora, some food components, and the immune 
system.1 Changes in the balance between regula‑
tory and inflammatory cytokines as well as endo‑
thelial dysfunction help maintain the inflamma‑
tory process.1 Endothelial cells form the padding 
of the interiors of blood vessels and provide a pro‑
tective barrier that regulates the flow of biomol‑
ecules and cells (eg, white blood cells) between 
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AbstrAct
IntroductIon Insulin ‑like growth factor 1 (IGF ‑1) is involved in the modulation of immunity and inflam‑
mation. It also plays a role in regulating the migration of endothelial cells and production of vasoactive 
agents.
objEctIvEs This study assessed the concentrations of IGF ‑1 and insulin ‑like growth factor‑binding protein 
3 (IGFBP ‑3) and their relationships to disease activity in patients with inflammatory bowel disease (IBD).
PAtIEnts And mEthods A total of 129 adult patients with IBD (69 with Crohn disease [CD] and 60 with 
ulcerative colitis [UC]) were involved in the study. The control group consisted of 31 healthy volunteers. 
Biochemical serum analyses were performed and the associations of IGF ‑1 and IGFBP ‑3 with inflamma‑
tory markers and disease activity were assessed.
rEsuLts IGF ‑1 levels were decreased in patients with active UC compared with those with nonac‑
tive UC (mean [SD], 78.3 [22.7] ng/ml and 96.2 [24.5] ng/ml, respectively; P = 0.02) and controls 
(94.5 [26.5] ng/ml; P = 0.03). The IGF ‑1 level was lower in patients with active CD compared with 
those with nonactive CD (mean [SD], 79.2 [24.9] ng/ml and 110.1 [43.4] ng/ml, respectively; P <0.001). 
The IGFBP ‑3 level was lower in patients with active UC compared with those with nonactive UC (P = 0.04) 
and controls (P = 0.04). IGF ‑1 correlated negatively with C ‑reactive protein (CRP) levels (P <0.01), 
disease activity (P <0.05), and disease duration (P <0.05). IGFBP ‑3 levels correlated negatively with 
CRP levels (P <0.05).
concLusIons The IGF system is disrupted in patients with IBD. Systemic levels of the IGF axis com‑
ponents are related to disease activity and duration.
orIGInAL ArtIcLE IGF ‑1 system in remission and flare of IBD 833
classic histological, endoscopic, and radiological 
criteria.21 The exclusion criteria were pregnancy, 
diabetes, immune diseases, other serious diseas‑
es, and chronic inflammatory processes.
The control group consisted of 31 healthy vol‑
unteers, including 13 men (41.9%) and 18 wom‑
en (58.1%); the median age was 39 years (IQR, 
31–45 years). All patients provided written in‑
formed consent to participate in the study. The 
study protocol was approved by the Jagiellonian 
University Ethics Committee.
clinical assessment Detailed histories of IBD 
were taken from all participants. Data on the fol‑
lowing parameters were collected: smoking hab‑
it, disease activity, disease duration, location 
of pathological changes, complications, cur‑
rent medications, and past surgical procedures. 
The Montreal classification was used to assess 
lesion location in patients with UC and CD.22 
Complications were defined as the presence of 
abscesses, fistulas, obstructions, or extraintes‑
tinal diseases associated with IBD.23
Disease activity was assessed according to 
the Crohn Disease Activity Index (CDAI) for pa‑
tients with CD and the Mayo Score for those 
with UC.24,25 Patients with CD were divided into 
2 subgroups based on CDAI scores: nonactive CD 
(CDAI score <150, n = 33 [47.8%]) and active CD 
(active CD; CDAI score ≥150, n = 36 [52.2%]).26 
Patients with UC were also divided into 2 sub‑
groups based on Mayo scores: nonactive UC (non‑
active UC; Mayo score = 1–3, n = 31 [51.7%]) 
and active UC (Mayo score ≥4, n = 29 [48.3%]).
Laboratory analyses Routine laboratory tests 
and complete blood counts were performed in all 
participants. Serum biochemical analyses includ‑
ed the examination of C ‑reactive protein (CRP), 
albumin, and fibrinogen levels. All tests were 
performed using routine methodology in clin‑
ical practice. Complete blood counts were per‑
formed with a Sysmex XE ‑2100 automated he‑
matological analyzer (Sysmex, Kobe, Japan). CRP 
and albumin levels were assayed using the Mod‑
ular P clinical chemistry analyzer (Roche Diag‑
nostics, Mannheim, Germany). Fibrinogen levels 
were measured with a Behring coagulation sys‑
tem (Dade Behring, Marburg, Germany). TNF‑
‑α and interleukin‑6 (IL ‑6) concentrations were 
determined by an enzyme ‑linked immunosor‑
bent assay (ELISA) with the ELISA Quantikine 
Immunoassay Kit (R&D Systems, Minneapolis, 
Minnesota, United States). The serum levels of 
IGF ‑1 and IGFBP ‑3 were determined by ELISA us‑
ing the Quantikine Human IGF ‑1 and IGFBP ‑3 
ELISA kits (R&D Systems).
statistical analysis Continuous data were pre‑
sented as means with standard deviations (nor‑
mally distributed data) or as medians with low‑
er and upper quartiles (skewed distributions). 
Discrete data were presented as frequencies and 
percentages. A 1 ‑way analysis of variance was 
One of the anti ‑inflammatory agents responsi‑
ble for proliferation of endothelial cells and an‑
giogenesis is insulin ‑like growth factor 1 (IGF ‑1), 
and its receptor is expressed in endothelial cells 
of small and large vessels.1,2,4
IGF ‑1 is a 7.5 ‑kDa peptide hormone produced 
primarily by mesenchymal cells in the liver.5,6 
Its production is regulated by growth hormone 
(GH) secreted by the pituitary gland.5,7 In serum, 
IGF ‑1 binds to a family of insulin ‑like growth fac‑
tor binding proteins (IGFBPs 1–6) that transport 
it to destination tissues.5 IGFBP ‑3 is the most 
abundant of the group of IGFBPs that trans‑
ports and, particularly, controls the bioavailabil‑
ity and half ‑life of IGF ‑1.6 IGF ‑1 receptors are 
located in many cell types, mainly in the brain, 
skeletal muscle, smooth muscle, cartilage, and 
bone.2,8,9 The serum IGF ‑1 concentration depends 
on the GH level, insulin level, nutritional status, 
and physical activity.7,10 IGF ‑1 promotes growth 
and differentiation in a variety of tissues, main‑
tains structural integrity, and inhibits apoptosis.7 
It is also involved in modulating immunity and 
inflammation.11 In addition, IGF ‑1 plays a major 
role in the function of endothelial cells2 by regu‑
lating their migration and producing vasoactive 
agents (eg, nitric oxide), and the correct level of 
IGF ‑1 contributes to protection from atheroscle‑
rosis and cardiovascular diseases.2 ,6,7 
Decreased serum concentrations of IGF ‑1 and 
IGFBP ‑3 occur in patients with type 2 diabetes 
mellitus and increase the risk of complications 
and mortality.12,13 Dysregulation of the IGF sys‑
tem affects angiogenesis and may contribute to 
malignancies.2 For example, systemic inflam‑
mation that can be found in rheumatoid arthri‑
tis results in resistance to GH and low circulat‑
ing IGF ‑1 levels.14-17 Baker et al18 reported that 
the IGF ‑1 level becomes progressively lower in pa‑
tients with more severe and long‑standing rheu‑
matoid arthritis. Tumor necrosis factor α (TNF‑α) 
inhibits IGF ‑1 during the chronic inflammation 
process.19 In addition, Briot et al20 showed that 
IGF ‑1 level increases in patients with ankylos‑
ing spondylitis who are treated with infliximab.
Our study investigated the associations be‑
tween IGF ‑1 and IGFBP ‑3 concentrations and 
clinical activity of UC and CD, as well as disease 
duration.
PAtIEnts And mEthods recruitment of pa-
tients Patients were recruited between Octo‑
ber 2016 and December 2016. The study includ‑
ed a total of 129 consecutive adult patients di‑
agnosed with IBD at the outpatient Department 
of Gastroenterology and Hepatology, Universi‑
ty Hospital in Krakow, Poland. Sixty ‑nine pa‑
tients were diagnosed with CD, including 36 
men (52.2%) and 33 women (47.8%); the medi‑
an age was 30 years (interquartile range [IQR], 
23–36 years). Sixty patients were diagnosed with 
UC, including 32 men (53.3%) and 28 women 
(46.7%); the median age was 36.5 years (IQR, 
25–46.76 years). IBD diagnoses were based on 
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for Statistical Computing, Vienna, Austria) was 
used for the calculations.
rEsuLts No significant difference in sex was 
observed among the UC, CD, and control groups 
(P = 0.6). The median age of patients with CD was 
lower than those of patients with UC (P = 0.02) 
and healthy participants (P = 0.004). The mean 
(SD) body mass index (BMI) was lower in the CD 
group than in the control group (21.6 [3.5] kg/m2 
vs 23.7 [3.4] kg/m2, respectively; P = 0.02). Sev‑
en patients (12%) with UC and 18 patients (26%) 
with CD had a BMI below 18.5 kg/m2, but only 
1 patient with UC and 5 patients with CD had 
a BMI below 17 kg/m2. There were 2 obese pa‑
tients, 1 in the CD group and 1 in the UC group. 
The  numbers of smokers were similar in all 
groups (P = 0.2). The extraintestinal complica‑
tions occurred more frequently in patients with 
CD (P = 0.006). Patients with CD were also more 
likely to have undergone surgery (P <0.001).
None of the analyzed patients had been bio‑
logically treated prior to the study. On enroll‑
ment, aminosalicylates were administered to all 
patients with IBD, immunosuppressants to 10 
patients with UC (17%) and 26 patients with CD 
(38%), and corticosteroids to 17 patients with UC 
(28%) and 23 patients with CD (33%). The dis‑
tribution of treatment used was not different in 
patients with UC and CD (P = 0.062).
The clinical characteristics of patients with ac‑
tive UC, nonactive UC, and healthy participants 
employed to compare the mean values among 
the 3 different populations, providing all assump‑
tions were met; otherwise, the Kruskal–Wallis 
test (for nonnormally distributed data) or Welch 
test (in case of heterogeneity) was applied. Addi‑
tionally, the post hoc Tukey test was performed 
in cases of significant results. Normality was ver‑
ified by the Shapiro–Wilk test, and homogeneity 
of variance was determined by the Levene test. 
The association between 2 continuous variables 
was investigated using the Pearson or Spearman 
rank correlation analysis, and the association be‑
tween 2 discrete variables was assessed by the χ2 
test or Fisher exact test.
Additional analyses were performed due to 
statistically significant differences in the mean 
age between the active CD and nonactive CD 
groups and healthy controls. Multiple linear re‑
gressions were applied to compare the means 
of selected features between these groups after 
adjusting for age. The interaction between age 
and disease activity was included in the mod‑
els. The Shapiro–Wilk test was used to verify 
whether the residuals were distributed normal‑
ly, and the Breusch–Pagan test was applied to 
investigate heteroscedasticity. Dependent vari‑
ables were transformed logarithmically in cas‑
es of nonnormally distributed residuals or het‑
eroscedasticity. The results were considered 
significant when P values were less than 0.05. 
The R software (version 3.3.2, The R Foundation 
tAbLE 1 Laboratory markers in patients with active and nonactive ulcerative colitis and control group
Parameter Nonactive UC
(n = 31)
Active UC
(n = 29)
Control group
(n = 31)
Male sex, n (%) 17 (54.8) 15 (51.7) 13 (41.9)
Age, y 29 (25–47.5) 40 (30–46) 39 (31–45)
Mayo score, points 2 (1–3)a 7 (6–9) NA
Disease duration, y 6 (2.5–9.5) 5 (2–9) NA
CRP, mg/l 1.2 (0.8–1.9)a 10 (7.4–42.2)b 0.65 (0.45–1.1)
WBC, ×103/µl 6.1 (5.3–7.3)a 8.9 (6.9–11.2)b 6.2 (4.9–7.7)
RBC, ×106/µl, mean (SD) 4.8 (0.6) 4.6 (0.5) 4.7 (0.4)
Hemoglobin, g/dl 13.8 (12.8–15)a 12.7 (11.7–13.8)b 14.3 (13.2–15.6)
Hematocrit, % 43.2 (39.3–44.6) 39.7 (36.8–42.2) 41 (38.6–44.6)
Platelets, ×103/µl 235 (201–288.5)a 316 (238–354)b 198 (185–251.5)
Albumin, g/l 45 (42.5–47.5)a 41 (35–43)b 47 (43.5–48)
Fibrinogen, g/l 2.6 (2.4–3.6)a 4.7 (3.6–6.4)b 2.7 (2.4–3)
TNF ‑α, mg/l 1.5 (1.2–2.4) 2.4 (1.4–3.6) 1.3 (0.9–1.6)
IL ‑6, pg/ml, 1.3 (.9–2.9)a 3.3 (1.6–9.9) 1.7 (1–2.9)
IGF ‑1, ng/ml, mean (SD) 96.2 (24.5)a 78.3 (22.7)b 94.5 (26.5)
IGFBP ‑3, ng/ml 2003.6a
(1777.8–2238.8)
1678.8b
(1411.7–200.2)
2038.3
(1677.1–3060)
Data are presented as median (interquartile range) unless otherwise stated.
a P <0.05 compared with active UC
b P <0.05 compared with the control group
Abbreviations: CRP, C ‑reactive protein; IGF ‑1, insulin ‑like growth factor 1; IGFBP ‑3, insulin ‑like growth factor‑binding protein 3; IL ‑6, 
interleukin 6; NA, not applicable; RBC, red blood cells; TNF ‑α, tumor necrosis factor α; UC, ulcerative colitis; WBC, white blood cells
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IGF ‑1 value in this group was 103.7 ng/ml (95% 
CI, 74.1–133.3) and did not differ significantly 
from the mean IGF ‑1 value in the noncorticoste‑
roid group (112.9 ng/ml; 95% CI, 93.5–132.3). In 
the active CD group, 13 of 36 patients (36.1%) re‑
ceived corticosteroids. The mean IGF ‑1 value in 
this group was 82.5 ng/ml (95% CI, 64.3–100.7) 
and did not differ significantly from the mean 
IGF ‑1 value in the  noncorticosteroid group, 
(77.3 ng/ml; 95% CI, 67.8–86.8).
Multiple linear regressions were performed 
due to significant differences in the mean age be‑
tween the active CD group, nonactive CD group, 
and healthy controls, as well as significant cor‑
relations between age and such variables as dis‑
ease duration (r = 0.3; P = 0.01), IGF ‑1 (r = −0.5; 
P <0.001), and IGFBP ‑3 (r = −0.3; P = 0.006). Log‑
arithmic transformation was applied to these 3 
variables because of nonnormally distributed 
residuals and/or heteroscedasticity. The results 
showed that the interaction term (age × group) 
and term with age only were not significant pre‑
dictors of the logarithm of disease duration. Also 
the interaction terms were not significant predic‑
tors of the logarithm of IGFBP ‑3, as opposed to 
age. It was a significant predictor of the logarithm 
of IGFBP ‑3 (β̂ = 0.01; P = 0.02). The IGFBP ‑3 lev‑
el in the study groups decreased by 0.99 each 
year. Notably, the mean disease duration and 
IGFBP ‑3 level did not differ significantly between 
the groups after adjusting for age.
are shown in tAbLE 1. The medians of the inflam‑
matory markers were higher in the active UC 
group than in the nonactive UC and control 
groups. Patients with active UC had a signifi‑
cantly higher median level of IL ‑6 than patients 
with nonactive UC. The mean IGF ‑1 concentra‑
tion and median IGFBP ‑3 concentration were 
lower in the active UC group than in the nonac‑
tive UC group and the control group.
Laboratory markers in the active CD, non‑
active CD, and control groups are presented in 
tAbLE 2. Patients with active CD demonstrated 
higher concentrations of inflammatory mark‑
ers, including TNF ‑α, compared with patients in 
the nonactive CD group and controls. The mean 
IGF ‑1 level was significantly lower in the active 
CD group than in the nonactive CD group. No 
difference in the median IGFBP ‑3 level was ob‑
served among the 3 studied populations.
In the nonactive UC group, only 1 person 
(3.2%) received corticosteroids. The IGF ‑1 value 
for this patient was 80.2 ng/ml, whereas the aver‑
age IGF ‑1 level for the remaining 30 participants 
was 96.7 ng/ml (95% confidence interval [CI], 
87.5–105.9). In the active UC group, 16 of 29 pa‑
tients (55.2%) received corticosteroids. The mean 
IGF ‑1 value in this group was 80.2 ng/ml (95% CI, 
66.3–94.2) and did not differ significantly from 
the mean IGF ‑1 value in the noncorticosteroid 
group (76 ng/ml; 95% CI, 65–87).
In the nonactive CD group, 10 of 33 patients 
(30.3%) received corticosteroids. The average 
tAbLE 2 Laboratory markers in patients with active and nonactive Crohn disease and control group
Parameter Nonactive CD
(n = 33)
Active CD
(n = 36)
Control group
(n = 31)
Male sex, n (%) 15 (45.5) 21 (58.3) 13 (41.9)
Age, y 30 (23–36)b 31 (23.8–36)b 39 (31–45)
CDAI score, points 70.4 (55–101.8)a 228 (172.4–287.3) NA
Disease duration, y 3 (2–6) 4 (2–7.3) NA
CRP, mg/l 1.5 (0.5–3.6)a 24.4 (16.1–62.2)b 0.65 (0.45–1.1)
WBC, ×103/µl 6.2 (5.6–7.2) 7 (5.4–9.4) 6.2 (4.9–7.7)
RBC, ×106/µl 4.8 (4.4–5.2) 4.8 (4.2–5) 4.7 (0.4)
Hemoglobin, g/dl 14.2 813.1–14.9)a 12.1 (10.9–13.2)b 14.3 (13.2–15.6)
Hematocrit, % 42.2 (40.1–45.5)a 37.9 (35–40.6)b 41 (38.6–44.6)
Platelets, ×103/µl 277 (215–305)a,b 324.5 (287.5–404.5)b 198 (185–251.5)
Albumin, g/l, mean (SD) 44.1 (3.8)a 38 (5.3)b 45.8 (2.7)
Fibrinogen, g/l 3.1 (2.6–4.2)a 5.2 (4.4–6.9)b 2.7 (2.4–3)
TNF ‑α, mg/l 1.1 (1–1.7)a 1.9 (1.4–3)b 1.3 (.9–1.6)
IL ‑6, pg/ml 1.3 (1–6.6)a 4.4 (2–6.6)b 1.7 (1–2.9)
IGF ‑1, ng/ml, mean (SD) 110.1 (43.4)a 79.2 (24.9) 94.5 (26.5)
IGFBP ‑3, ng/ml 2001.8
(1863.6–2191.5)
1881.4
(1714.4–2121)
2038.3
(1677.1–3060)
Data are presented as median (interquartile range) unless otherwise stated.
a P <0.05 compared with active CD
b P <0.05 compared with the control group
Abbreviations: CD, Crohn disease; CDAI, Crohn Disease Activity Index; others, see tAbLE 1
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value of the logarithm of IGF ‑1 in the nonac‑
tive CD group differed from that in the control 
group by 0.54–0.02 × age (P = 0.03). No signif‑
icant interaction was found between the active 
CD group and the control group (P = 0.9). In this 
situation, lower values of the logarithm of IGF ‑1 
were not significantly related to age. The differ‑
ence in the mean logarithm of IGF ‑1 between 
the active CD and control groups remained sta‑
ble, regardless of age.
The correlations of IGF ‑1 and IGFBP ‑3 with 
the other parameters in all patient groups are 
presented in tAbLEs 3 and 4, respectively.
dIscussIon This study is the first to demon‑
strate that plasma IGF ‑1 levels are lower in pa‑
tients with active UC and active CD than in pa‑
tients in remission. Similarly, the mean IGFBP ‑3 
level was lower in patients with UC flares. In 
addition, this study showed that IGF ‑1 in pa‑
tients with IBD was correlated negatively with 
clinical activity of the disease, disease duration, 
and inflammatory markers. On the other hand, 
IGFBP ‑3 was correlated negatively with inflam‑
matory markers and disease activity in patients 
with UC.
Eivindson et al27 demonstrated that the serum 
IGF ‑1 level is correlated negatively with CRP lev‑
els and positively with albumin levels in patients 
with IBD, whereas IGFBP ‑3 is correlated positive‑
ly with the albumin level in patients with IBD and 
negatively with the UC activity; however, no sig‑
nificant difference in the mean IGF ‑1 or IGFBP ‑3 
value was shown during disease flares or remis‑
sions. The authors concluded that the IGF sys‑
tem of proteins is associated with the activity of 
the inflammatory state, which was confirmed by 
our finding of lower IGF ‑1 concentrations in pa‑
tients during IBD flares, as well as differences in 
IGFBP ‑3 concentrations in those with active UC. 
Street et al,28 who analyzed data from 37 pa‑
tients with CD and UC, observed that the IGF ‑1 
Significant interaction terms were discovered 
in the case of the IGF ‑1 marker. The mean values 
of the logarithm of IGF ‑1 in the nonactive CD 
group differed from those in the active CD group 
by 0.78–0.02 × age (P = 0.03) (FIGurE 1). Similar 
age ‑related differences were found between 
the nonactive CD and control groups. The mean 
Disease activity
             Nonactive CD
             Active CD
             Controls
Age
20 30 40 50 60 70
Lo
g 
(IG
F-
1)
3.5
4.0
4.5
5.0
FIGurE 1 Scatterplot 
of insulin ‑like growth 
factor 1 (IGF ‑1) and age 
according to Crohn 
disease activity
tAbLE 3 Coefficients of correlation between insulin ‑like growth factor 1 and given 
properties in the populations separately
Parameter UC
(n = 60)
CD
(n = 69)
Control 
group
(n = 31)
CRP, mg/l r = –0.4
P = 0.002
r = –0.3
P = 0.009
NS
WBC, ×103/µl NS NS NS
RBC, ×106/µl NS NS NS
Hemoglobin, g/dl NS r = 0.3
P = 0.02
NS
Hematocrit, % NS r = 0.3
P = 0.02
NS
Platelets, ×103/µl NS r = –0.3
P = 0.04
NS
Albumin, g/l r = 0.3
P = 0.02
r = 0.3
P = 0.03
NS
Fibrinogen, g/l r = –0.4
P = 0.003
r = –0.4
P = 0.003
NS
TNF ‑α, mg/l NS NS NS
IL ‑6, pg/ml r = –0.3
P = 0.02
NS NS
CDAI / Mayo scores r = –0.3
P = 0.02
r = –0.4
P = 0.003
NA
Disease duration, y r = –0.3
P = 0.01
r = –0.3
P = 0.02
NA
IGFBP ‑3, ng/ml r = 0.4
P = 0.002
r = 0.5
P <0.001
r = 0.38
P = 0.035
Abbreviations: NS, nonsignificant; others, see tAbLEs 1 and 2
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Our study also demonstrated a negative corre‑
lation between IGF ‑1 and IBD duration in the CD 
and UC groups. Similar observations were report‑
ed by Baker et al18 for patients with rheumatoid 
arthritis. This phenomenon may be related to in‑
creased catabolism due to increased disease dura‑
tion, which may be responsible for disturbances 
in the the GH/IGF ‑1 axis.27 Katsanos et al29 sug‑
gested that the decreases in IGF ‑1 and IGFBP ‑3 
levels in patients with active IBD could be asso‑
ciated with acquired GH resistance, which can be 
caused by inflammatory cytokines.
Numerous patients with IBD also suffer from 
osteopenia or osteoporosis, and they show lower 
calcium and phosphate levels as compared with 
healthy people.32 A decrease in the concentration 
of IGF ‑1, hormone responsible for normal growth 
of bones and muscles, as well as a decrease in 
the level of IGFBP ‑3 are among the factors con‑
tributing to muscle weakness and osteoporosis 
in patients with IBD.28,31,33,34 These abnormali‑
ties intensify with prolonged disease duration. 
Van Langenberg et al33 found that a decrease in 
the IGF ‑1 level was associated with muscle weak‑
ening in patients with CD; however, disease du‑
ration was not considered and the analysis did 
not include patients with UC. Among the stud‑
ies of osteoporosis in patients with IBD, only 
Koutroubakis et al34 analyzed correlations be‑
tween the IGF ‑1 and IGFBP ‑3 levels and the in‑
tensification of osteoporosis in patients with 
IBD. They noted a weak positive correlation be‑
tween IGFBP ‑3 and bone mineral density of the 
femoral neck. The authors concluded that low 
concentrations of IGF ‑1 and IGFBP ‑3 might de‑
crease bone mineral density.
An important factor that might contribute 
to the development of osteoporosis in patients 
with IBD is the use of glucocorticoids. Glucocor‑
ticoids affect differentiation and function of os‑
teoblasts, metabolism, and function of osteo‑
cytes; moreover, they are involved in the regu‑
lation of GH secretion.35 Glucocorticoid excess 
may suppress the peripheral expression of GH‑
‑receptors impairing the IGF ‑1 synthesis;35 how‑
ever, high therapeutic doses have been shown 
to increase IGF ‑1 levels, while the bioavailabili‑
ty of this hormone is reduced.5 In our study, we 
did not observe significant differences in IGF ‑1 
levels between patients who received glucocor‑
ticoids and those who did not.
IGF ‑1 acts as a vasodilator. Individuals with 
GH deficits and low IGF ‑1 levels manifest endo‑
endothelial dysfunction and abnormalities of va‑
sodilation depending on nitric oxide produced by 
endothelial cells.36 Earlier in vivo studies dem‑
onstrated that IGF ‑1 stimulation induces en‑
dothelial nitric oxide synthase.37 Nitric oxide is 
a key factor in the maintenance of normal vas‑
cular homeostasis.1 Its production is disturbed 
by asymmetric dimethylarginine (ADMA), which 
is an endogenous inhibitor of endothelial nitric 
oxide synthase.38 ADMA has been recognized as 
a marker of endothelial dysfunction, and ADMA 
level was lower in patients with CD compared 
with healthy participants only during disease 
flares. In addition, the IGFBP ‑3 level did not dif‑
fer between these groups. However, the authors 
defined a disease flare as a CRP concentration 
exceeding 1.5 mg/l and erythrocyte sedimenta‑
tion rate exceeding 20 mm/h, which may have 
resulted in the failure to appropriately identify 
some patients with disease flares. On the oth‑
er hand, Katsanos et al29 analyzed data from 22 
patients with newly diagnosed IBD (not divid‑
ed into CD and UC subgroups) and demonstrat‑
ed a decrease in IGF ‑1 and IGFBP ‑3 levels in af‑
fected participants compared with healthy indi‑
viduals who were matched for age, sex, and BMI. 
The results of our study, which was performed 
with more participants and included the analy‑
ses of the CD and UC subgroups during disease 
flares and remission, confirmed abnormalities in 
the IGF axis functioning during active inflamma‑
tion in patients with IBD.
Interesting results were obtained in stud‑
ies carried out with IGFBP ‑3 knockout mice, in 
which UC was induced by administering dextran 
sodium sulfate. IGFBP ‑3 knockout mice demon‑
strated a less active inflammatory state and low‑
er levels of IL ‑6, TNF ‑α, and IL ‑1β, as well as in‑
creased proliferation of intestinal endothelial 
cells leading to repair of the endothelial barrier, 
which might confirm the role of the IGF axis in 
the development of the inflammatory state in pa‑
tients with IBD.30 In turn, an experimental study 
performed by Harris et al31 in mice with colitis 
induced by dextran sodium sulfate showed a de‑
crease in the level of plasma IGF ‑1; these results 
are concordant with our observations in adult 
patients with IBD.
tAbLE 4 Coefficients of correlation between insulin ‑like growth factor binding protein 
3 and given properties in the populations separately
UC
(n = 60)
CD
(n = 69)
Control group
(n = 31)
CRP, mg/l r = –0.4
P = 0.004
r = –0.3
P = 0.01
NS
WBC, ×103/µl r = –0.3
P = 0.05
NS NS
RBC, ×106/µl NS NS NS
Hemoglobin, g/dl NS NS NS
Hematocrit, % NS NS NS
Platelets, ×103/µl NS NS r = 0.4
P = 0.04
Albumin, g/l NS NS NS
Fibrinogen, g/l r = 0.3
P = 0.02
NS NS
TNF ‑α, mg/l NS NS NS
IL ‑6, pg/ml NS NS NS
CDAI / Mayo scores r = –0.3
P = 0.01
NS NA
Disease duration, y NS NS NA
Abbreviations: see tAbLEs 1, 2, and 3
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In conclusion, our results show that the IGF 
system is disrupted in patients with IBD. The sys‑
temic levels of the IGF axis components are relat‑
ed to disease activity and duration. Our results 
support the role of the IGF axis in the patho‑
genesis of IBD.
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